Development of a Drug Delivery System for Cancer Immunotherapy.
Delivery systems are a powerful technology for enhancing the effect of cancer immunotherapy. We have been in the process of developing lipid-based delivery systems for controlling the physical properties and dynamics of immunofunctional molecules such as antigens and adjuvants. The lipid nanoparticulation of these molecules improves their physical properties, resulting in a good water dispensability, greater stability, and small size. The cell wall skeleton of bacille Calmette-Guerin (BCG-CWS) could be used to replace live BCG as a drug for treating bladder cancer, but problems associated with the physical properties of BCG-CWS have prevented its use. To overcome such problems, we developed a novel packaging method that permits BCG-CWS to be encapsulated into lipid nanoparticles, which induce antitumor responses against bladder cancer. Lipid nanoparticulation also improves the intracellular trafficking and biodistribution of immunofunctional molecules. Cyclic di-GMP (c-di-GMP) is an adjuvant that is recognized by the cytosolic sensor. However, c-di-GMP cannot pass through the cell membrane. We encapsulated c-di-GMP into lipid nanoparticles containing a pH-responsive lipid that was developed in our laboratory and achieved efficient cytosolic delivery and the induction of antitumor immunity. Furthermore, we are attempting to control the functions of immune cells by RNA interference. We have recently succeeded in the efficient delivery of small interfering RNA into mouse dendritic cells (DCs), which led to the enhancement of antitumor activity of DCs. In this review, our recent efforts regarding cancer immunotherapy using lipid-based nanoparticles are reviewed.
Laboratory for Molecular Design of Pharmaceutics, Faculty of Pharmaceutical Sciences, Hokkaido University.
Takashi
T
Nakamura
D000276:Adjuvants, Immunologic; D000818:Animals; D017358:Cell Wall Skeleton; D006152:Cyclic GMP / Q000031:analogs & derivatives; D003713:Dendritic Cells; D016503:Drug Delivery Systems; D015195:Drug Design; D006801:Humans; D007167:Immunotherapy; D008055:Lipids; D051379:Mice; D009163:Mycobacterium bovis; D053758:Nanoparticles; D009369:Neoplasms / Q000628:therapy*; D034622:RNA Interference; D001749:Urinary Bladder Neoplasms / Q000628:therapy
D000276:Adjuvants, Immunologic; D017358:Cell Wall Skeleton; D008055:Lipids; C062025:bis(3',5')-cyclic diguanylic acid; D006152:Cyclic GMP